Actuate Therapeutics reports preclinical melanoma data showing up to 77% tumor growth inhibition

Actuate Therapeutics announced that oral dosing of its investigational drug elraglusib reduced tumor growth by as much as 77% in a mouse melanoma model, with twice‑daily dosing outperforming once‑daily dosing. The study, presented at the 38th EORTC‑NCI‑AACR Symposium, also showed enhanced CD8+ T‑cell and NK‑cell activity in tumors. Actuate intends to begin a Phase 1/2 study in Q1 2027, enrolling patients who have refractory metastatic melanoma.

The company says the preclinical exposure‑response data support moving the oral formulation into humans, so the upcoming Phase 1/2 trial could advance the pipeline and affect ACTU’s valuation. The announcement lifted ACTU’s share price, indicating market interest in the candidate.

  • 1Oral elraglusib achieved up to 77% tumor growth inhibition with twice‑daily dosing in a B16F10 melanoma mouse model.
  • 2Once‑daily oral dosing produced 50% tumor growth inhibition in the same model.
  • 3The preclinical results were presented at the 38th EORTC‑NCI‑AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026).
  • 4Actuate plans to start a Phase 1/2 clinical trial in the first quarter of 2027, enrolling patients with refractory metastatic melanoma.
  • 5Shares rose 13.58% to $0.28 following the announcement.

Sources